President Trump has put Germany on notice over drug pricing, launching a formal trade probe and warning that America will not subsidize foreign health systems forever. This piece explains the case against Germany’s low drug prices, the economics behind innovation, the Section 301 probe, the U.K. precedent, and why forcing fairness matters for American patients and workers.
For years European governments have leaned on U.S. drugmakers, demanding deep discounts and setting prices that undercut the market. That approach skews the costs of research and development onto American companies and, ultimately, U.S. taxpayers and patients. The Trump administration says enough is enough and is taking concrete steps to push back.
On June 18 the administration announced a major investigation into German drug pricing, a clear shot across the bow of a long-standing imbalance. The probe centers on what officials call “persistent underpayment for innovative pharmaceutical products.” The public hearing scheduled for Sept. 22 will give the government time to gather evidence and decide whether countermeasures are warranted.
The economics here are straightforward but brutal: a new drug costs about $2.7 billion on average to develop, according to industry estimates. When foreign markets force steep discounts, companies must make up revenue elsewhere, usually on home turf. That means higher prices for Americans or fewer breakthroughs down the line.
Germany and other European nations have built systems that, intentionally or not, transfer costs to U.S. consumers and innovators. They demand low prices and then import American-made medicines, enjoying the benefits of U.S. investment without paying full freight. From a Republican standpoint, that is freeloading we should not tolerate.
By pressing a Section 301 investigation, the Trump administration is using traditional trade tools to address an unusual form of economic unfairness. If the probe finds that German policies unduly harm American innovation, tariffs or other remedies could follow. Those are blunt instruments, but Presidents can and should use them to defend U.S. workers and industry when diplomacy and negotiation fail.
Predictably, German officials reacted with alarm and warned of wider fallout for U.S.-EU trade relations. That response is telling: if current policies were truly sustainable and fair, there would be little reason to object to scrutiny. Instead, outrage is a sign that powerful interests prefer the status quo, even if it shifts costs onto American families.
The U.K. offers a recent example of how confrontation can change outcomes. After pressure from Washington, British negotiators agreed to adjustments that reduced the unfair burden Americans were carrying. It was not a perfect fix, but it showed that tough trade diplomacy can yield results that better protect U.S. interests.
Standing firm on drug pricing is not just about corporate profits; it is about preserving an American innovation engine that saves lives. When companies can recoup their investments, they hire workers here and fund the next wave of treatments for cancer, Alzheimer’s, and rare diseases. Letting other nations underpay weakens that incentive structure.
Critics will call this protectionism or claim it risks retaliation, but the alternative is passive acceptance of a system that violates basic fairness. The Trump administration’s posture sends a clear message: the United States will defend its innovators and taxpayers. If foreign partners want access to U.S. medicines, they should pay a fair share for the privilege.
Americans deserve policies that prioritize patients and U.S. jobs over foreign price manipulation. If Germany adjusts its pricing practices, patients on both sides of the Atlantic will benefit from healthier markets and sustained innovation. If it refuses, Washington has tools and the political will to respond.
TRUMP EXPANDS TRUMPRX PRESCRIPTION DRUG DISCOUNT PROGRAM TO MORE THAN 800 MEDICATIONS
